Dynacor Group Inc. (TSX: DNG)
The World’s Publically Traded Processor of Artisanal Gold
AbbVie (ABBV) announced in June that it would acquire Apogee Therapeutics (APGE) for $10.9 billion in cash, sparking a core concern among investors: Will this massive expenditure affect the company’s proud dividend payout program? For a “Dividend King” that has raised its dividend for 54 consecutive years, any transaction that could potentially threaten its dividend record deserves careful scrutiny.
Debt Financing Preserves Cash Reserves, Providing Ample Dividend Safety Margin
First and foremost, it should be made clear that AbbVie will fund this acquisition through debt financing, meaning its cash reserves will not be significantly depleted. As of the end of 2025, AbbVie held $17.8 billion in free cash flow, and in the first quarter of 2026, net revenue reached $15.002 billion, representing 12.4% year-over-year growth — the company’s fundamentals remain solid. More critically, the company’s dividend payouts over the past 12 months accounted for only 59% of its free cash flow, which means that even after factoring in the additional debt burden from the acquisition, the existing payout level still enjoys a substantial margin of safety.
The Allergan Precedent Proves Major Acquisitions Don’t Disrupt Dividends
Market concerns are not entirely unfounded — $10.9 billion is a significant sum for any company. However, AbbVie’s historical track record provides the most compelling answer. In May 2020, AbbVie completed its acquisition of Allergan for $63 billion in a mix of cash and stock — the largest transaction in the company’s history and one of the largest pharmaceutical industry mergers ever. Even so, AbbVie’s dividend payouts were not only unaffected but have since grown by a cumulative 46.6%. This precedent demonstrates management’s unwavering commitment to maintaining its dividend growth record — if the company were to interrupt its dividend increases for even a single year, it would need to wait another 50 years to rejoin the ranks of the Dividend Kings.
Acquisition Target Zumilokibart Poised to Become a Long-Term Growth Engine
From a strategic perspective, the long-term significance of this acquisition further supports dividend sustainability. The core asset being acquired is zumilokibart — an investigational drug for the treatment of atopic dermatitis (eczema) that has completed Phase 2 clinical studies. The drug’s differentiating advantage lies in its long-acting dosing mechanism: patients would need only one injection every 3 to 6 months, a significant improvement in treatment adherence compared to the current mainstream therapies requiring injections every 2 to 4 weeks. If it successfully passes Phase 3 trials and receives regulatory approval, this product is expected to become another growth engine for AbbVie in the immunology space, further solidifying its leadership in the field.
Core Growth Drivers Remain Robust
Meanwhile, AbbVie’s existing product portfolio continues to demonstrate strong growth. In the first quarter of 2026, core immunology drug Skyrizi generated $4.483 billion in global revenue, up 30.9% year-over-year, while Rinvoq contributed $2.119 billion, representing 23.3% growth. The company has raised its 2026 adjusted earnings per share guidance to the range of $14.08 to $14.28. Currently, AbbVie offers a dividend yield of approximately 2.7% and trades at a forward price-to-earnings ratio of about 18 times, remaining attractive for long-term income-focused investors.
